Physician-Scientist Early Investigator and Thoracic Oncologist at the NCI. All views and tweets are my own and do not reflect those of the NIH or government.
@MontessaLee Hi Montessa - I am a lung cancer researcher at the NCI in Bethesda, MD. Would you be willing to assist as an advocate for a career development award grant in SCLC? If so, please email me at [email protected]. Many thanks for your consideration.
In science we depend on @FedEx to safely and quickly move reagents between labs (even during the pandemic). We have yet to receive a valuable, overnight package after 3 days. Can @FedExHelp provide some help?
New postdoctoral position is available in my laboratory to study neuroendocrine tumor immunology using novel patient-derived organoids and translational studies in upcoming clinical trials with @JaydiDelRivero https://t.co/islLfS9Kln
In our new paper @NatureComms we have uncovered mechanistic insights into why only a small minority of patients with relapsed small cell lung cancer respond to immunotherapy. https://t.co/KhuYcdgJDx @NCIResearchCtr @theNCI
@chulkimMD@drgandara@drgandara@chulkimMD 2 explanations - 1. MET amp is a subclonal resistance mechanism (spatial heterogeneity) and 2. MET amp appears at first or second osi progression (temporal heterogeneity). Pts with longer response to osi did not evidence of MET amp
Check out our paper taking a deep dive into EGFR mutant lung cancer resistance mechanisms in very first issue of @CellRepMed. This was translational research at its best, a collaborative effort of medical/radiation oncology, surgery and bioinformatics. https://t.co/R21RyQ47KX
Whoo!! Our paper using multi-region phylogeny to explore the resistance mechanisms of EGFR mutant lung cancer is out! I'm really proud of the work we put into this and it's great to see it out in the world and in the very first issue of @CellRepMed
https://t.co/EtpC3qTcWy